Emiltatug Ledadotin (Emi-Le, XMT-1660)
Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort)
Servier (registry sponsor Day One Biopharmaceuticals) · Phase 1/2 · Recruiting · Enrollment 360
| Arm | Reported safety |
|---|---|
| Emi-Le, ACC efficacy cohort | n/r |
| Emi-Le, post hoc aggressive subtype | n/r |
| Emi-Le, ACC safety cohort | grade 3 treatment-related adverse events: 79.2%, ASCO 2026treatment-related discontinuation: 2.1%, ASCO 2026dose reduction: 45.8%, ASCO 2026 |
| EMBLEM-1 pivotal Phase 2 cohort | n/r |
A count stays a count. This page does not turn a count into a percent.